Skip to main content

Nextech Invest Ltd.

13F filer · CIK 0001595430
Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$2.11BU.S. long equity reported on 13F
Positions151 new · 3 closed
Net flow last quarter-$102MBuys minus sells
Top 10 positions weight98.0%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202615 positions
RVMDRevolution Medicines, Inc.$1.42B67.55%3.55%Not reportedQ1 2025
PBLSParabilis Medicines, Inc.$128M6.06%3.82%NewQ2 2026
RLAYRelay Therapeutics, Inc.$127M6.02%3.10%+22.6%Q1 2025
TYRATyra Biosciences, Inc.$114M5.39%5.96%-12.4%Q1 2025
ALMSAlumis Inc.$99.6M4.73%Not reportedNot reportedQ1 2025
ORICOric Pharmaceuticals, Inc.$77.6M3.68%6.91%Not reportedQ1 2025
KYMRKymera Therapeutics, Inc.$32M1.52%0.34%Not reportedQ2 2025
ZYMEZymeworks Inc.$29.1M1.38%1.56%Not reportedQ1 2025
GLUEMonte Rosa Therapeutics, Inc.$18.4M0.87%0.89%+150.2%Q4 2025
ARVNArvinas, Inc.$17.1M0.81%1.72%+108.1%Q1 2025
CTMXCytomX Therapeutics, Inc.$16.7M0.79%2.04%Not reportedQ1 2026
SLNSilence Therapeutics plc$10.5M0.50%0.67%Not reportedQ1 2025
CRVSCorvus Pharmaceuticals, Inc.$6.72M0.32%0.53%Not reportedQ1 2026
CNTXContext Therapeutics Inc.$4.11M0.20%8.08%Not reportedQ1 2025
ENGNenGene Therapeutics Inc.$4.02M0.19%3.47%Not reportedQ4 2025
Q1 2026Reported May 15, 202617 positions
RVMDRevolution Medicines, Inc.$739M52.02%3.80%Not reportedQ1 2025
TYRATyra Biosciences, Inc.$155M10.93%6.82%Not reportedQ1 2025
TNGXTango Therapeutics, Inc.$152M10.70%5.04%Not reportedQ1 2025
ORICOric Pharmaceuticals, Inc.$90.8M6.39%6.92%Not reportedQ1 2025
ALMSAlumis Inc.$78M5.49%Not reported+21.4%Q1 2025
RLAYRelay Therapeutics, Inc.$55M3.87%2.92%+17.6%Q1 2025
ZYMEZymeworks Inc.$27.9M1.96%1.52%Not reportedQ1 2025
KYMRKymera Therapeutics, Inc.$23.2M1.63%0.34%Not reportedQ2 2025
CTMXCytomX Therapeutics, Inc.$20.9M1.47%2.61%NewQ1 2026
CNTXContext Therapeutics Inc.$19.4M1.37%8.08%Not reportedQ1 2025
CGEMCullinan Therapeutics, Inc.$16.2M1.14%1.86%Not reportedQ1 2025
ENGNenGene Therapeutics Inc.$15.8M1.11%3.47%+9.4%Q4 2025
CRVSCorvus Pharmaceuticals, Inc.$6.58M0.46%0.54%NewQ1 2026
ARVNArvinas, Inc.$5.72M0.40%0.84%Not reportedQ1 2025
SLNSilence Therapeutics plc$5.02M0.35%0.67%Not reportedQ1 2025
GLUEMonte Rosa Therapeutics, Inc.$5M0.35%0.36%+9.0%Q4 2025
SPRYARS Pharmaceuticals, Inc.$4.9M0.35%0.62%-7.6%Q1 2025
Q4 2025Reported Feb 17, 202616 positions
RVMDRevolution Medicines, Inc.$605M58.53%3.86%Not reportedQ1 2025
TYRATyra Biosciences, Inc.$107M10.31%7.55%Not reportedQ1 2025
TNGXTango Therapeutics, Inc.$64.4M6.22%5.35%+31.3%Q1 2025
ORICOric Pharmaceuticals, Inc.$58.6M5.66%7.27%Not reportedQ1 2025
RLAYRelay Therapeutics, Inc.$39.8M3.85%2.70%+22.2%Q1 2025
ZYMEZymeworks Inc.$29.3M2.84%1.49%Not reportedQ1 2025
ALMSAlumis Inc.$28.5M2.75%Not reportedNot reportedQ1 2025
KYMRKymera Therapeutics, Inc.$21.7M2.10%0.34%-18.2%Q2 2025
ENGNenGene Therapeutics Inc.$19.2M1.85%3.17%NewQ4 2025
MRSNMersana Therapeutics, Inc.$14M1.35%9.66%Not reportedQ1 2025
CGEMCullinan Therapeutics, Inc.$11.8M1.14%1.89%Not reportedQ1 2025
CNTXContext Therapeutics Inc.$10.9M1.05%8.08%Not reportedQ1 2025
SPRYARS Pharmaceuticals, Inc.$7.7M0.74%0.67%Not reportedQ1 2025
ARVNArvinas, Inc.$6.4M0.62%0.85%-61.7%Q1 2025
SLNSilence Therapeutics plc$5.79M0.56%0.67%Not reportedQ1 2025
GLUEMonte Rosa Therapeutics, Inc.$4.38M0.42%0.43%NewQ4 2025
Q3 2025Reported Nov 14, 202515 positions
RVMDRevolution Medicines, Inc.$355M54.03%4.01%Not reportedQ1 2025
ORICOric Pharmaceuticals, Inc.$86M13.08%7.36%Not reportedQ1 2025
TYRATyra Biosciences, Inc.$56.7M8.64%7.61%Not reportedQ1 2025
TNGXTango Therapeutics, Inc.$46.5M7.08%4.96%Not reportedQ1 2025
RLAYRelay Therapeutics, Inc.$20.1M3.06%2.23%Not reportedQ1 2025
KYMRKymera Therapeutics, Inc.$19.3M2.94%0.48%Not reportedQ2 2025
ZYMEZymeworks Inc.$19M2.90%1.48%Not reportedQ1 2025
ARVNArvinas, Inc.$12M1.83%1.99%Not reportedQ1 2025
ALMSAlumis Inc.$11.6M1.77%Not reportedNot reportedQ1 2025
CNTXContext Therapeutics Inc.$7.19M1.09%8.08%Not reportedQ1 2025
CGEMCullinan Therapeutics, Inc.$6.77M1.03%1.93%Not reportedQ1 2025
SPRYARS Pharmaceuticals, Inc.$6.64M1.01%0.67%-10.9%Q1 2025
SLNSilence Therapeutics plc$4.94M0.75%0.67%Not reportedQ1 2025
MRSNMersana Therapeutics, Inc.$3.75M0.57%9.66%-96.0%Q1 2025
BOLDBoundless Bio, Inc.$1.51M0.23%5.49%Not reportedQ1 2025
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.